[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Nippon Shinyaku Co. Ltd.
Morgan Stanley downgrades Nippon Shinyaku due to patent concerns, but the RGX-121 partnership offers a positive outlook. Social engagement is up, indicating growing interest in the stock's performance and developments in its partnerships and treatments for diseases like MPS II (Hunter syndrome).
About Nippon Shinyaku Co. Ltd.
Nippon Shinyaku Co. Ltd. is a pharmaceutical company.
Price: $ #
Price 24-Hour Time-Series Raw Data
The price action is likely influenced by the Morgan Stanley downgrade due to the Uptravi patent cliff, as well as positive news regarding the RGX-121 partnership. The market cap is undefined, which may indicate a lack of recent trading activity or data availability.
1-Year High: $XXXXX on 2024-11-28
1-Year Low: $XXXXX on 2025-07-14
AltRank: undefined #
AltRank 24-Hour Time-Series Raw Data
Nippon Shinyaku Co. Ltd. is currently AltRank #undefined based on combined combined social and market metrics
Daily Average: XXXXX
1-Year High: XXXXX on 2024-12-11
1-Year Low: XXX on 2025-01-15
Galaxy Score: XX #
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-01-14
1-Year Low: XX on 2024-10-26
Engagements: XX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
1 Week: XX -XX%
1 Month: XXX +75%
6 Months: XXXXX -XX%
1 Year: XXXXXXX -XX%
1-Year High: XXXXXX on 2025-01-14
1-Year Low: X on 2024-12-04
| Social Network | X | TikTok | YouTube |
|---|---|---|---|
| Engagements | X | X | X |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
6 Months: XX -XX%
1 Year: XXX +64%
1-Year High: XX on 2025-01-14
1-Year Low: X on 2024-10-26
| Social Network | X | TikTok | YouTube |
|---|---|---|---|
| Mentions | X | X | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning Nippon Shinyaku Co. Ltd. in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
6 Months: XX -XX%
1 Year: XXX +51%
1-Year High: XX on 2025-01-14
1-Year Low: X on 2024-10-18
Market Cap: $undefined #
Market Cap 24-Hour Time-Series Raw Data
Current Value: $undefined
Daily Average: $XXXXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXXXX on 2024-11-28
1-Year Low: $XXXXXXXXXXXXXXX on 2025-02-03
Top assets mentioned In the posts about Nippon Shinyaku Co. Ltd. in the last XX hours
Top topics mentioned In the posts about Nippon Shinyaku Co. Ltd. in the last XX hours
$rgnx, morgan stanley, stocks financial services, $200m, $150m, $110m, $clpt, cuts, japanese yen, mi
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Morgan Stanley downgrades Nippon Shinyaku stock on Uptravi patent cliff concerns -"
X Link @patesalo_e 2025-08-27T09:42Z 1663 followers, XX engagements
"Morgan Stanley downgrades Nippon Shinyaku to Underweight on Uptravi patent cliff cuts PT to JPY 2600"
X Link @byul_finance 2025-08-27T09:11Z XXX followers, XX engagements
"$rgnx $clpt Neurodegenerative Disease: Clemidsogene lanparvovec (RGX-121) is a potential first-in-class treatment for MPS II also known as Hunter syndrome being developed and potentially commercialized in partnership with Nippon Shinyaku. In May 2025 the U.S. Food and Drug Administration (FDA) granted priority review of the BLA seeking accelerated approval for clemidsogene lanparvovec for MPS II; Prescription Drug User Fee Act (PDUFA) target action date of November X 2025. The FDA BLA review is progressing as planned; mid-cycle meeting and PLI and BIMO inspections were successfully completed."
X Link @mike98572986 2025-08-07T11:16Z XXX followers, 1343 engagements
"$rgnx $200m cash from abbv $150m from prv $110m from Nippon Shinyaku Will receive $460m in cash this year"
X Link @jw929204 2025-01-14T11:42Z XXX followers, 2701 engagements